Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Thursday morning. The brokerage issued a hold rating on the medical research company’s stock.

CTSO has been the topic of several other reports. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a report on Monday, January 13th. HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $1.05 on Thursday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The business’s 50 day moving average price is $0.96 and its 200 day moving average price is $1.04. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The firm has a market cap of $57.41 million, a P/E ratio of -2.92 and a beta of 0.61.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Thursday, November 7th. The medical research company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The business had revenue of $9.39 million during the quarter, compared to analysts’ expectations of $10.14 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. During the same period last year, the company earned ($0.21) earnings per share. On average, sell-side analysts expect that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Institutional investors have recently bought and sold shares of the company. Skylands Capital LLC lifted its position in shares of Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after acquiring an additional 26,195 shares in the last quarter. Sargent Investment Group LLC raised its stake in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Cytosorbents during the 4th quarter worth $99,000. Finally, Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents during the third quarter worth $51,000. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.